Aspirin Enteric Coated Tablets belong to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs). It prevents blood cells, or platelets, from producing thromboxane. It is this substance that can cause platelets to clump together and start off the process of blood clotting. This can be dangerous, as it could cause a blockage that cuts off the blood supply to an organ. A blockage in the arteries supplying blood to the heart or brain can cause a heart attack or stroke.
People with angina, or who have already suffered a heart attack or stroke, are at risk of having another because of the atherosclerosis in their arteries and in this case, low dose aspirin is used to lower the risk of this.
This dosage of aspirin is not to be used for pain relief.
Precautions to consider before taking Aspirin Enteric Coated 75mg Tablets:
Consult with your doctor before starting this treatment for blood thinning. Aspirin Enteric Coated 75mg Tablets are not to be used for pain relief.
· There is a possible association between aspirin and Reye's syndrome when given to children. Reye's syndrome is a very rare disease, which affects the brain and liver, and can be fatal. For this reason aspirin should not be given to children aged under 16 years unless specifically indicated (e.g. for Kawasaki's disease).
· Salicylates may enhance the effect of oral hypoglycaemic agents, phenytoin and sodium valproate. They inhibit the uricosuric effect of probenecid and may increase the toxicity of sulphonamides.
· Aspirin may potentiate the effect of heparin and increases the risk of bleeding with oral anticoagulants, antiplatelet agents and fibrinolytics.
· Plasma salicylate concentrations may be reduced by concurrent use of corticosteroids, and salicylate toxicity may occur following withdrawal of the corticosteroids. The risk of gastrointestinal ulceration and bleeding may be increased when aspirin and corticosteroids are co-administered.
· Concurrent use of aspirin and other NSAIDs should be avoided. Use of two or more NSAID preparations increases the risk of serious gastrointestinal haemorrhage. Concurrent administration of carbonic anhydrase inhibitors such as acetazolamide and salicylates may result in severe acidosis and increased central nervous system toxicity. In large doses, salicylates may also decrease insulin requirements. Patients using enteric coated aspirin should be advised against ingesting antacids simultaneously to avoid premature drug release.
· Before commencing long-term aspirin therapy for the management of cerebrovascular or cardiovascular disease patients should consult their doctor who can advise on the relative benefits versus the risks for the individual patient.
· Aspirin decreases platelet adhesiveness and increases bleeding time. Haematological and haemorrhagic effects can occur, and may be severe. Patients should report any unusual bleeding symptoms to their physician.
· Salicylates should be used with caution in patients with a history of peptic ulceration or coagulation abnormalities. They may also induce gastro-intestinal haemorrhage, occasionally major.
· They may also precipitate bronchospasm or induce attacks of asthma in susceptible subjects.
· Aspirin should be used with caution in patients with impaired renal function (avoid if severe), or in patients who are dehydrated.
· Patients with hypertension should be carefully monitored.
You should carefully read all product packaging and labels prior to use
